In addition, PDE1C is predicted to interact with dyphylline (DB00651), a drug approved for asthma, bronchospasm, and chronic obstructive pulmonary disease (COPD) (Ding et al., 2012; Wishart et al., 2018; Zhao et al., 2019). Here, PDE1C is linked to chronic obstructive pulmonary disease.